Peter Kornicker - Novartis Chief Compliance Officer

NVSEF Stock  USD 95.68  0.71  0.74%   

Executive

Dr. Peter Kornicker was Chief Compliance Officer at Novartis AG since January 2011. He leads the Integrity Compliance Function which designs and implements compliance programs associated with the Novartis Code of Conduct AntiBribery Policy and Professional Practices Policies. Mr. Kornicker joined Novartis in 1994 and has held legal roles of increasing responsibility in Switzerland and the United States at business units including Pharmaceuticals Animal Health Corporationrationrate and Consumer Health. Prior to being appointed Chief Compliance Officer he served as Global General Counsel for the Consumer Health Division since 2011.
Tenure 13 years
Professional MarksPh.D
Phone41 61 324 1111
Webhttps://www.novartis.com
Kornicker received his law degree in 1991 and his doctorate in 1993 from the University of Basel. He was admitted to the bar in 1994.

Novartis Management Efficiency

The company has return on total asset (ROA) of 0.0645 % which means that it generated a profit of $0.0645 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1093 %, meaning that it generated $0.1093 on every $100 dollars invested by stockholders. Novartis' management efficiency ratios could be used to measure how well Novartis manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 20.24 B in total debt with debt to equity ratio (D/E) of 0.47, which is about average as compared to similar companies. Novartis AG has a current ratio of 1.28, suggesting that it may not be capable to disburse its financial obligations in time and when they become due. Debt can assist Novartis until it has trouble settling it off, either with new capital or with free cash flow. So, Novartis' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Novartis AG sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Novartis to invest in growth at high rates of return. When we think about Novartis' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

EXECUTIVE Age

Charles SawyersNovartis AG ADR
62
Joerg KoglinMerck Company
N/A
Dalton IIIMerck Company
57
Urs JaisliRoche Holding
62
Karl MahlerRoche Holding
N/A
Joseph RomanelliMerck Company
N/A
Cristina WilburRoche Holding
56
Thomas LarsenAstraZeneca PLC ADR
N/A
Jessica MooreJohnson Johnson
N/A
Erwin VanhaeckeNovartis AG ADR
N/A
Mark LarkinsJohnson Johnson
N/A
Shannon KlingerNovartis AG ADR
49
Jeffrey GeorgeNovartis AG ADR
41
John TsaiNovartis AG ADR
54
Chirfi GuindoMerck Company
58
Michele GalenNovartis AG ADR
N/A
Richard FrancisNovartis AG ADR
50
Andrin OswaldNovartis AG ADR
41
Robert WeltevredenNovartis AG ADR
52
Jeffrey PottAstraZeneca PLC ADR
N/A
William PaoRoche Holding
51
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company was incorporated in 1996 and is headquartered in Basel, Switzerland. Novartis operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. It employs 104323 people. Novartis AG [NVSEF] is a Pink Sheet which is traded between brokers as part of OTC trading.

Management Performance

Novartis AG Leadership Team

Elected by the shareholders, the Novartis' board of directors comprises two types of representatives: Novartis inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Novartis. The board's role is to monitor Novartis' management team and ensure that shareholders' interests are well served. Novartis' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Novartis' outside directors are responsible for providing unbiased perspectives on the board's policies.
Ton Buechner, Non-Executive Independent Director
Robert PharmD, Chief Officer
Verena Briner, Non-Executive Independent Member of the Board
Karen Hale, Chief Officer
Chris Ilsley, President CEO
Steven Baert, Head of HR
Richard Saynor, Chief Sandoz
Richard Francis, Member of the Executive Committee and Division Head, Sandoz
Daniel Vasella, Honorary Chairman of the Board
Pierre Landolt, Member of the Board of Directors
Elizabeth Doherty, Non-Executive Independent Director
Erwin Vanhaecke, Head Novartis Group Quality
Elizabeth Barrett, CEO, Novartis Oncology
Mark Fishman, Member of the Executive Committee and President of Novartis Institute for BioMedical Research (NIBR)
Charlotte PamerWieser, Corporate Secretary
Shannon Klinger, Chief Risk and Compliance Officer, Group General Counsel
Samir Shah, Global Head Investor Relations
David Epstein, Member of the Executive Committee, Division Head, Pharmaceuticals
Srikant Datar, Member of the Board of Directors
MarieFrance Tschudin, Pres Officer
Samir MD, Global Relations
Francesco Balestrieri, CEO of Sandoz, Member of the Executive Committee
Steffen Lang, Global Head of Novartis Technical Operations, Member of the Executive Committee
Paul Penepent, Head Accounting
Joerg Reinhardt, Chairman of the Board
Paul Hudson, CEO of Novartis Pharmaceuticals, Member of the Executive Committee
Brian McNamara, Member of the Management Board, Division Head, Novartis OTC
Michele Galen, Head Communications
Charles Sawyers, Non-Executive Independent Member of the Board
John Tsai, Head of Global Drug Development and Chief Medical Office, Member of the Executive Committee
Dimitri Azar, Member of the Board of Directors
Frans Houten, Non-Executive Independent Director
Nancy Andrews, Non-Executive Independent Director
Susanne Schaffert, CEO Novartis Oncology, Member of the Executive Committee
Enrico Vanni, Member of the Board of Directors
Bertrand Bodson, Chief Digital Officer, Member of the Executive Committee
Robert Weltevreden, Head of Novartis Business Services (NBS), Member of the Executive Committee
Andre Wyss, Member of the Executive Committee, Novartis Business Services and Country President for Switzerland
Bruno Strigini, CEO of Novartis Oncology, Member of the Executive Committee
Vasant Narasimhan, Global Head of Drug Development and Chief Medical Officer for Novartis, Member of the Executive Committee
Alex Krauer, Honorary Chairman of the Board
Michael Ball, CEO of Alcon, Member of the Executive Committee
Jeffrey George, Member of the Executive Committee and Division Head, Sandoz
Peter Kornicker, Chief Compliance Officer
Andreas Planta, Member of the Board of Directors
Joseph Jimenez, CEO, Member of the Executive Committee
Ulrich Lehner, Vice Chairman of the Board of Directors, Non-Executive Director
William Winters, Non-Executive Independent Member of the Board
Ann Fudge, Member of the Board of Directors
George Gunn, Member of the Executive Committee, Division Head, Novartis Animal Health of Head, Corporate Responsibility
Paul Arkel, Head of Corporate Strategy and External Affairs
James Bradner, President of the Novartis Institutes for BioMedical Research (NIBR), Member of the Executive Committee
Klaus Moosmayer, Chief Ethics Risk and Compliance Officer, Member of the Executive Committee
Felix Ehrat, General Counsel and General Counsel of Novartis International Ag
Harry Kirsch, Chief Officer
Andrin Oswald, Member of the Executive Committee, Division Head, Vaccines and Diagnostics

Novartis Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Novartis a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Novartis in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Novartis' short interest history, or implied volatility extrapolated from Novartis options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novartis AG. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income.
Note that the Novartis AG information on this page should be used as a complementary analysis to other Novartis' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.

Complementary Tools for Novartis Pink Sheet analysis

When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.
Equity Valuation
Check real value of public entities based on technical and fundamental data
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Please note, there is a significant difference between Novartis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Novartis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novartis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.